RPE Induction Method Using Segmented Signaling Pathways

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for inducing retinal pigment epithelial cells are time-consuming and result in cells with poor functionality and low survival rates, limiting their effectiveness for transplantation treatments in retinal degenerative diseases.

Innovation Solution

A method involving three stages - differentiation of ectoderm, pigment epithelial precursor cell differentiation, and maturation of retinal pigment epithelial cells - using specific signaling pathways and culture media (RDM1, RDM2, RDM3, RDM4, RMM, and REM media) to efficiently induce iPSCs into functional RPE cells, significantly reducing production time and improving cell vitality.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current differentiation methods are used to induce RPE cells, then cell transplantation can be performed, but the induction time is long (90-140 days) and cell functionality is poor

Engineering Contradiction:
Improvecell functionalityVSAvoidinduction time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The differentiation process is divided into three distinct stages: neural induction stage (days 0-6), RPE specification stage (days 7-14), and maturation stage (days 15-28). Each stage uses specific culture media and signaling pathway modulators to achieve optimal results at each step, reducing total induction time to 28 days while improving cell functionality.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent systematically changes multiple parameters including culture media composition (RDM1, RDM2, RDM3, RDM4, RMM, REM), signaling pathway modulators (BMP inhibitors, Wnt inhibitors, TGF-β inhibitors, ROCK inhibitors), and growth factors to optimize differentiation efficiency and reduce induction time while maintaining high cell functionality.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If current differentiation methods are used, then RPE cells can be produced, but survival rate after transplantation is low

Engineering Contradiction:
Improvesurvival rateVSAvoidtransplantation effectiveness
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The maturation stage (days 15-28) is designed to pre-adapt RPE cells to physiological conditions before transplantation. This includes exposure to appropriate oxygen tension, nutrient composition, and signaling molecules that mimic the in vivo retinal environment, thereby improving post-transplantation survival rate and long-term functionality.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The differentiated RPE cells are encouraged to activate endogenous survival pathways and form functional networks autonomously during the maturation stage, reducing reliance on external support factors after transplantation and improving long-term survival without continuous external intervention.

Inventive Principle:
Principle #25Self-service

Data Source

PatentUS20240240141A1Rapid and efficient clinical grade pigment epithelium induction method, kit, and application
Publication Date: 2024.07.18 ALLIFE MEDICINE (ZHUHAI) LTD
  • US20240240141A1 patent drawing
  • US20240240141A1 patent drawing
  • US20240240141A1 patent drawing

AI summary

A rapid and efficient clinical grade pigment epithelium induction method, a kit, and an application. Provided is a method for rapidly and efficiently inducing retinal pigment epithelium (RPE). IPSCs are directionally induced in three stages, such that an RPE generation duration can be greatly shortened. Specifically, the method comprises using a culture medium containing a small molecule compound for cell culture, the small molecule compound comprising a BMP signaling pathway inhibitor, a Wnt pathway inhibitor, inhibitors for TGF-BI receptors ALK5, ALK4 and ALK7, a ROCK pathway inhibitor, a WNT signaling pathway activator, a VEGFR kinase inhibitor, a GSK signaling pathway inhibitor, a VEGFR kinase inhibitor, vitamins, and the like.